BioPharma Dive· BioPharma Dive staff·· 16 小时前评分22
2026年Q4值得关注的5项FDA决定：ivonescimab、giredestrant、anito-cel等
5 FDA decisions to watch in the fourth quarter of 2026
导读
BioPharma Dive梳理2026年Q4值得关注的5项FDA决定：Summit/Akeso的PD-1/VEGF双抗ivonesc
来源：BioPharma Dive · biopharmadive.com